Commercial-grade APIs and reference standards manufactured via automated solid-phase platforms with comprehensive mass spec verification.
The tripeptide sequence Arg-Gly-Asp (RGD) is the definitive recognition motif mediating cell adhesion, integrin affinity, and targeted molecular oncology.
Linear RGD motifs often exhibit broad-spectrum, low-affinity cross-reactivity. Through head-to-tail cyclization, specifically cyclic pentapeptides such as cyclo(RGDfK) and cyclo(RGDyK), our automated platforms impose spatial restrictions on the aspartate carboxyl and arginine guanidinium groups, boosting selectivity specifically for αvβ3 and αvβ5 integrins over αIIbβ3.
Monomeric RGD targets frequently encounter rapid renal clearance and modest in vivo residency. Thinheal engineers dimeric [c(RGDfK)]2 and tetrameric RGD dendrimers linked via PEGylated or lysine branching nodes. This polyvalent design leverages the avidity effect, increasing cell surface binding affinities by up to 100-fold in neo-vascular imaging.
We provide chemical modification strategies integrating macrocyclic chelators (DOTA, NOTA), cytotoxic warheads (MMAE, DM1), and fluorescent dyes (Cy5.5, FITC). Synthesis routes employ orthogonal protecting groups (Alloc, Dde, Mtt) to execute functionalization without perturbing the pharmacophoric RGD triangle.
Strategic advancements transitioning integrin research into clinically translatable targeted radiopharmaceuticals and bio-responsive biomaterials.
Integrating 68Ga, 177Lu, and 225Ac radionuclides with stable cyclic RGD conjugates for real-time PET imaging directly paired with targeted alpha/beta-emitting radiotherapy.
Self-assembling RGD-grafted ECM scaffolds tailored to instruct stem cell osteogenesis, corneal repair, and endothelial alignment via mechanical shear-thinning matrices.
Post-insertion peptide-lipid anchoring systems functionalizing lipid nanoparticles (LNPs) with c(RGDyK) to enable cell-specific mRNA, siRNA, and gene editor delivery.
Replacing standard residues with N-methylated, beta-amino acids or halogenated aromatics (e.g., fluoro-phenylalanine) to defeat endogenous protease degradation in human serum.
End-to-end industrial architecture serving clinical pipelines, academic centers, and large-molecule biopharma leaders globally.
Turnkey custom peptide drug conjugate (PDC) synthesis. We supply high-affinity cyclic RGD molecules conjugated to clinical cytotoxic payloads with acid-labile or cathepsin-cleavable linkers, achieving direct tumor cell cytotoxicity without systemic marrow toxicity.
Bulk production of ultra-pure research- and medical-device-grade linear and cyclic RGD peptide conjugates for electrospinning and titanium implant functionalization, ensuring rapid tissue osseointegration and suppressed bacterial adhesion.
Full CMC validation workflows: analytical method development (RP-HPLC, LC-MS/MS, UPLC), impurity characterization, chiral analysis of D-amino acid optical purity, and ICH Q1A accelerated stability documentation across all production tiers.
Hangzhou Thinheal Pharma-Tech deploys automated solid-phase synthesizer matrices and multi-ton downstream purification assets, ensuring uninterrupted global delivery.
Our facility runs continuous synthesis trains using microwave-assisted and flow-chemistry protocols, mitigating side-chain aggregation and steric hindrance on hydrophobic amino acids while maximizing overall peptide yield.
Industrial dynamic axial compression (DAC) columns spanning 150mm to 600mm diameters enable high-throughput separation of deletion sequences, stereoisomers, and beta-aspartyl side products at pilot and commercial multi-kilogram batches.
Integrated sterile freeze-drying systems operating under continuous differential pressure, certified for low bioburden and precise residual moisture manipulation down to < 3.0%, protected by real-time SCADA parameter monitoring.
Indicative pricing matrix designed for procurement executives, contract research directors, and industrial procurement auditors.
| Peptide / Derivative Name | Sequence / Chemical Architecture | Purity (HPLC) | Batch Scale Tier | Reference Price (USD) | Lead Time |
|---|---|---|---|---|---|
| Linear RGD Tripeptide | H-Arg-Gly-Asp-OH (TFA / Acetate) | ≥ 98.0% | 100g - 1kg | $2.80 - $4.50 / g | 5 - 7 Days |
| Cyclo(RGDfK) Standard | cyclo[Arg-Gly-Asp-D-Phe-Lys] | ≥ 98.5% | 10g - 50g | $45.00 - $68.00 / g | 10 - 14 Days |
| Cyclo(RGDyK) High Affinity | cyclo[Arg-Gly-Asp-D-Tyr-Lys] | ≥ 98.5% | 50g - 250g | $55.00 - $80.00 / g | 12 - 16 Days |
| DOTA-c(RGDfK) Conjugate | DOTA-Ahx-cyclo(Arg-Gly-Asp-D-Phe-Lys) | ≥ 95.0% - 98.0% | 1g - 10g | $220.00 - $350.00 / g | 2 - 3 Weeks |
| Biotinylated RGD Probe | Biotin-Ahx-Arg-Gly-Asp-Ser-OH | ≥ 98.0% | 5g - 25g | $38.00 - $55.00 / g | 7 - 10 Days |
| Dimeric RGD Peptide E[c(RGDyK)]2 | Glu[cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 | ≥ 95.0% - 98.0% | 5g - 50g | $140.00 - $190.00 / g | 2 - 3 Weeks |
| Custom Commercial Scale RGD | cGMP Route Designed Custom Conjugates | ≥ 99.0% | 1kg - 25kg+ | Custom Quote / CDMO Project | Scheduled Campaign |
*Note: Pricing subject to raw amino acid cost index, counter-ion selection (Acetate vs. TFA), and specific release testing specifications.
Complete regulatory dossiers, localized logistical handling, and multi-jurisdictional compliance protocols.
Extensive support with Drug Master Files (DMF), US FDA, EMA, and NMPA technical documentation covering process route, impurities, and validation.
Validated removal of residual trifluoroacetic acid (TFA), achieving quantitative acetate or hydrochloride counter-ion conversions (< 0.1% TFA) for in vivo preclinical safety.
Worldwide validated temperature-controlled freight logistics (-20°C / -80°C lyophilized shipments) with integrated real-time temperature data-logging.
Multi-lingual technical sales teams spanning the Americas, Europe, Russia/CIS, Middle East, and Asia to assist procurement teams in real time.
Scale-ready peptide products optimized for metabolic disorders, oncology, neurodegenerative therapy, and clinical trial pipelines.
Authoritative technical and commercial clarifications directly addressing the concerns of research teams and procurement managers.
Thin